GemPharmatech Co., Ltd. (SHA:688046)
China · Delayed Price · Currency is CNY 18.39
+0.05 (0.27%)
At close: Jan 22, 2026
GemPharmatech Revenue
GemPharmatech had revenue of 200.77M CNY in the quarter ending September 30, 2025, with 18.56% growth. This brings the company's revenue in the last twelve months to 752.70M, up 11.13% year-over-year. In the year 2024, GemPharmatech had annual revenue of 686.84M with 10.39% growth.
Revenue (ttm)
752.70M
Revenue Growth
+11.13%
P/S Ratio
10.02
Revenue / Employee
476.99K
Employees
1,578
Market Cap
7.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 686.84M | 64.65M | 10.39% |
| Dec 31, 2023 | 622.19M | 105.64M | 20.45% |
| Dec 31, 2022 | 516.55M | 122.76M | 31.17% |
| Dec 31, 2021 | 393.79M | 131.87M | 50.35% |
| Dec 31, 2020 | 261.92M | 69.20M | 35.91% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 2.81B |
| Kexing Biopharm | 1.52B |
| Xiangxue Pharmaceutical | 1.47B |
| Nanjing Vazyme Biotech | 1.34B |
| Shanghai Medicilon | 1.08B |
| Wuhan Keqian Biology Co.,Ltd | 1.01B |
| Beijing Konruns Pharmaceutical | 871.31M |
| R&G PharmaStudies | 789.45M |